EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dry powder formulations of hyperimmune serum

Annalisa Bianchera iD, Gaetano Donofrio iD, Fabio Sonvico iD, Ruggero Bettini iD

Drug Delivery and Translational Research · 2025

DOI: 10.1007/s13346-024-01678-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Annalisa Bianchera und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Food and Drug Sciences, University of Parma, Parco Area Delle Scienze 27/a, 43124, Parma, Italy. Hauptthemen laut MEDLINE: SARS-CoV-2, COVID-19, Antibodies, Viral. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università degli Studi di Parma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Effective strategies against the spread of respiratory viruses are needed, as tragically demonstrated during the COVID-19 pandemic. Apart from vaccines, other preventive or protective measures are necessary: one promising strategy involves the nasal delivery of preventive or protective agents, targeting the site of initial infection. Harnessing the immune system’s ability to produce specific antibodies, a hyperimmune serum, collected from an individual vaccinated against SARS-CoV-2, was formulated as a dry powder for nasal administration. The selection of adequate excipients and process are key to maintaining protein stability and modulating the aerodynamic properties of the powders for reaching the desired respiratory regions. To this end, a hyperimmune serum was formulated with trehalose and mannitol as bulking agents during spray drying, then the ability of the redissolved immunoglobulins to bind Spike protein was verified by ELISA; foetal bovine serum was formulated in the same conditions as a reference. Moreover, a seroneutralization assay against SARS-CoV-2 pseudoviruses generated from different variants of concern was performed. The neutralizing ability of the serum was slightly reduced with respect to the starting serum when trehalose was used as a bulking agent. The powders were loaded in hypromellose capsules and aerosolized employing a nasal insufflator in an in vitro model of the nasal cavity connected to a Next Generation Impactor. The analysis of the powder distribution confirmed that all powders were inhalable and could target, at the same time, the upper and the lower airways. This is a preliminary proof-of-concept that this approach can constitute an effective strategy to provide broad coverage and protection against SARS-CoV-2, and in general against viruses affecting the airway. According to blood availability from donors, pools of hyperimmune sera could be rapidly formulated and administered, providing a simultaneous and timely neutralization of emerging viral variants. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2COVID-19Antibodies, ViralPowdersHumansTrehaloseMannitolAdministration, IntranasalAnimalsExcipientsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingDrug CompoundingCOVID-19 Serotherapy

Stichwörter der Autor:innen

Hyperimmune serumImmunoglobulins formulationInhalable powdersProphylaxisViral neutralization

Substanzen

PowdersTrehaloseMannitolExcipientsAntibodies, ViralSpike Glycoprotein, CoronavirusAntibodies, Neutralizingspike protein, SARS-CoV-2

Autor:innen und Institutionen

  • Department of Food and Drug Sciences, University of Parma, Parco Area Delle Scienze 27/a, 43124, Parma, Italy.
  • Interdepartmental Research Centre for the Innovation of Health Products, University of Parma, Parco Area Delle Scienze, Biopharmanet-TecPadiglione 33, 43124, Parma, Italy.
  • Department of Medical-Veterinary Science, University of Parma, Via del Taglio 10, 43126, Parma, Italy.
  • Department of Food and Drug Sciences, University of Parma, Parco Area Delle Scienze 27/a, 43124, Parma, Italy. ruggero.bettini@unipr.it.
  • Interdepartmental Research Centre for the Innovation of Health Products, University of Parma, Parco Area Delle Scienze, Biopharmanet-TecPadiglione 33, 43124, Parma, Italy. ruggero.bettini@unipr.it.

ORCID-Profile: Annalisa Bianchera, Gaetano Donofrio, Fabio Sonvico, Ruggero Bettini

Förderung

  • Università degli Studi di Parma

Zitieren

APA

Bianchera, A., Donofrio, G., Sonvico, F., & Bettini, R. (2025). Dry powder formulations of hyperimmune serum. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01678-8

Vancouver

Bianchera A, Donofrio G, Sonvico F, Bettini R. Dry powder formulations of hyperimmune serum. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-024-01678-8

BibTeX
@article{Bianchera2025,
  author = {Bianchera, Annalisa and Donofrio, Gaetano and Sonvico, Fabio and Bettini, Ruggero},
  title = {Dry powder formulations of hyperimmune serum},
  journal = {Drug Delivery and Translational Research},
  year = {2025},
  doi = {10.1007/s13346-024-01678-8}
}
Kostenlos starten →